Fig. 7: SARS-CoV-2 neutralization following GFPDL peptide immunization.
From: SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19
a,b, SARS-CoV-2 neutralization titers of serum from rabbits immunized with GFPDL-identified SARS-CoV-2 spike peptides or control RSV p27 peptide by PsVN assay using either 293T-hACE2 (a) or Calu-3 (b) cells. Sera from rabbits immunized with SARS-CoV-2 prefusion spike protein, RBD protein or heat-killed SARS-CoV-2 virions were used as comparators. The data (50% neutralization titers; PsVNA50) represent the median value of two rabbits immunized with each immunogen from assays run in duplicate. Pre-vaccination rabbit sera did not neutralize SARS-CoV-2 tested in PsVN assay. Samples were fresh and not thawed. All samples were run in one batch at the same time for each assay. Differences among groups were analyzed using multiple-group comparisons by non-parametric (Kruskal–Wallis) statistical testing using Dunn’s post hoc analysis in GraphPad Prism. The differences were considered statistically significant with a 95% confidence interval when the P value was less than 0.05 (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).
